Canadian Website

Espanol English

» Browse All Offices

Did you know?

LLS Therapy Acceleration Program partner, Celator, has completed their targeted enrollment of 120 first relapsed AML patients for their phase II trial of their liposomal drug CPX-351.

• Academic Grants
  • Career Development Program
    • Review Panel
    • Quality of Life Research Initiative
  • Translational Research Program
    • Review Panel
    • Quality of Life Research Initiative
  • Specialized Center of Research Program
    • Review Panel
  • Screen to Lead Program
  • The New Idea Award
  • The Quest for Cures
  • Myelofibrosis Challenge Grant
  • Other Grant Opportunities
  • Grants In Force
  • Request and Reporting Forms
• Drug Development Partnerships
  • Therapy Acceleration Program (TAP)
    • TAP Pipeline
• Continuing Medical Education
  • Past Programs for CME Credit
  • Cellular Metabolism in Hematologic Malignancies: From Evolving Science to Therapeutic Potential
  • Shared Care of Patients
  • Sharing Care for Survivors of Hematologic Malignancies
• Continuing Education
  • Past Programs for CE Credit
  • Sharing Care for Survivors of Hematologic Malignancies
  • Administration & Management of Current Therapies for Hematologic Malignancies
  • PTCL - Diagnosis & Treatment Update
  • Living with Slow-Growing Lymphoma
  • Living With Myeloma - Treatment and Side Effects Management

The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Privacy Policy  |  Security  |  Copyright  |  Link Policy  |  Disclaimer  |  Refund Policy  |  Public Disclosure

• 
• 
• 
•